Edesa Biotech Inc

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its pipeline includes EB05, a monoclonal antibody in Phase 3 for acute respiratory distress syndrome, and EB01, a topical non-steroidal anti-inflammatory cream that has completed Phase 3 for chronic allergic contact dermatitis. It also develops EB07, a monoclonal antibody in Phase 2 for pulmonary fibrosis, and EB06, a human monoclonal antibody candidate that binds to CXCL10 and inhibits its interaction with receptors CXCR3A and CXCR3B. The company has collaboration agreements with NovImmune SA and Yissum Research Development Company, and was founded in 2015 with headquarters in Markham, Canada.